Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Adjuvant and Down-Staging Treatment with Imatinib in Gastrointestinal Stromal Tumours
Linköpings universitet, Hälsouniversitetet, Hälsouniversitetets läkarutbildning.
2008 (engelsk)Independent thesis Advanced level (professional degree), 10 poäng / 15 hpOppgave
Abstract [en]

Background: GISTs are gastrointestinal mesenchymal tumours that express the type III receptor tyrosine kinase KIT. The KIT proto-oncogene encodes the receptor KIT. Most GISTs have gain-of-function mutations in the KIT or PDGFRA gene. The tyrosine kinase is therefore continuously activated leading to ligand-independent dimerization. Imatinib mesylate (Glivec®) is considered to be the first-line palliative treatment. The activated form of the KIT receptor tyrosine kinase is inhibited by imatinib. The aim of the study was to compare the survival of patients treated with either adjuvant or down-staging imatinib with historic controls treated with radical surgery (R0) only.

Methods: A historic control group was chosen from a population-based series from western Sweden (population 1.6 million) that matched the adjuvant (n=23) and down-staging (n=7) groups respectively. Mutation analysis was performed in all cases with bidirectional direct sequencing. The recurrence-free survival was calculated.

Results: There was only one recurrence (4 %) in the adjuvant group, and no recurrences in the down-staging study group, compared to 32/48 patients (67 %) in the control group. Tumour size decreased in diameter from 20 cm to 11 cm with down-staging treatment.

Conclusion: Adjuvant imatinib improves recurrence-free survival in R0 resected patients. Down-staging treatment with imatinib is recommended for patients with large tumours or metastases. The importance of mutation analysis was established.

sted, utgiver, år, opplag, sider
Hälsouniversitetets läkarutbildning , 2008. , s. 25
Emneord [en]
GIST, imatinib, adjuvant, down-staging, neoadjuvant, mutation, KIT, PDGFRA
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-11060ISRN: LIU-LÄKARPRG-D--08/001--SEOAI: oai:DiVA.org:liu-11060DiVA, id: diva2:17512
Fag / kurs
Medical Programme, Scientific Project
Presentation
2007-11-28, 00:00
Uppsök
Agriculture, Veterinary Medicine, Forestry
Veileder
Examiner
Tilgjengelig fra: 2008-02-19 Laget: 2008-02-19 Sist oppdatert: 2012-04-24bibliografisk kontrollert

Open Access i DiVA

fulltekst(2089 kB)759 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 2089 kBChecksum MD5
8fd7a0b6c14971492fb9623395c5b1d9c3f399faf637e03595d82343b74813377b6fa456
Type fulltextMimetype application/pdf

Av organisasjonen

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 759 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

urn-nbn

Altmetric

urn-nbn
Totalt: 1257 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf